Dott.ssa Martina Biggioggero

Istruzione e Formazione

• • Laurea specialistica in Medicina e Chirurgia presso Università degli Studi di Milano in data 26/07/05
• • Specializzazione in Reumatologia presso Università degli Studi di Milano in data 02/04/12
• • Master di II livello in “Clinical problem solving in reumatologia” presso Università degli Studi di Milano in data 11/01/17

Pubblicazioni

• • Favalli EG, Selmi C, Becciolini A, Biggioggero M, Ariani A, Santilli D, Fusaro E, Parisi S, Massarotti M, Marchesoni A, Meroni PL. Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: A multi-center retrospective analysis. Arthritis Care Res (Hoboken). 2016 Oct 1.
• • Becciolini A, Biggioggero M, Favalli EG. The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry. J Int Med Res. 2016 Sep;44(1 suppl):113-118.
• • Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Biggioggero M, Benucci M, Li Gobbi F, Grossi V, Infantino M, Meacci F, Manfredi M, Guiducci S, Bellando-Randone S, Matucci-Cerinic M, Foti R, Di Gangi M, Mosca M, Tani C, Palmieri F, Goletti D; Italian board for the Tailored BIOlogic therapy (ITABIO).. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum. 2016 Apr;45(5):519-32.
• • Favalli EG, Becciolini A, Biggioggero M. Structural integrity versus radiographic progression in rheumatoid arthritis. RMD Open. 2015 Aug 15;1(Suppl 1):e000064.
• • Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, Meroni PL. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. Arthritis Care Res (Hoboken). 2016; 8(4):432-9.
• • Bazzani C, Scrivo R, Andreoli L, Baldissera E, Biggioggero M, Canti V, Gerosa M, Pontikaki I, Ramoni V, Trespidi L, Zatti S, Caporali R, Gorla R, Iannone F, Lojacono A, Meroni P, Montecucco C, Motta M, Sabbadini MG, Valesini G, Tincani A. Prospectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs: an Italian multicentre study. Clin Exp Rheumatol. 2015 Sep-Oct;33(5):688-93.
• • Favalli EG, Biggioggero M, Marchesoni A, Meroni PL. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford). 2015 Jul;54(7):1337.
• • Biggioggero M, Danova M, Genovese U, Locatelli F, Meroni PL, Pane F, Scaglione F. The challenging definition of naïve patient for biological drug use. Autoimmun Rev. 2015 Jun;14(6):543-6.
• • Biggioggero M, Favalli EG. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides. Drug Dev Res. 2014 Nov;75 Suppl 1:S38-41.
• • Favalli EG, Becciolini A, Biggioggero M, Marchesoni A, Meroni PL. Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry. Ann Rheum Dis. 2015 Jan;74(1):e5
• • Favalli EG, Biggioggero M, Meroni PL. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug? Autoimmun Rev. 2014 Nov;13(11):1102-8.
• • Sebastiani M, Anelli MG, Atzeni F, Bazzani C, Farina I, Fedele AL, Favalli EG, Fineschi I, Cino N, Dal Forno I, Gasparini S, Cassarà E, Giardina R, Bruschi E, Addimanda O, Cassone G, Lopriore S, Sarzi-Puttini P, Filippini M, Pignatti F, Gremese E, Biggioggero M, Manganelli S, Amato G, Caimmi C, Salaffi F, Iannone F, Ferri C, Sandri G, Lapadula G, Gorla R, Govoni M, Ferraccioli G, Marchesoni A, Galeazzi M, Foti R, Carletto A, Cantini F, Triolo G, Epis OM, Salvarani C; Italian Study Group on Early Arthritides (GISEA).. Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register. Joint Bone Spine. 2014 Dec;81(6):508-12.
• • Favalli EG, Bugatti S, Biggioggero M, Caporali R. Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. Biomed Res Int. 2014;2014:831603.
• • Favalli EG, Biggioggero M, Marchesoni A, Meroni PL. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford). 2014 Sep;53(9):1664-8. Erratum in: Rheumatology (Oxford). 2015 Jul;54(7):1337.
• • Favalli EG, Pregnolato F, Biggioggero M, Meroni PL. The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis. Semin Arthritis Rheum. 2014 Jun;43(6):730-7.
• • Meroni PL, Biggioggero M, Pierangeli SS, Sheldon J, Zegers I, Borghi MO. Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. Nat Rev Rheumatol. 2014 Jan;10(1):35-43.
• • Favalli EG, Pregnolato F, Biggioggero M, Meroni PL. The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials. Ther Adv Musculoskelet Dis. 2012 Aug;4(4):213-23.
• • Biggioggero M, Gabbriellini L, Meroni PL. Type I interferon therapy and its role in autoimmunity. Autoimmunity. 2010 Apr;43(3):248-54
• • Biggioggero M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev. 2010 Mar;9(5):A299-304.
• • Biggioggero M, Borghi MO, Gerosa M, Trespidi L, Cimaz R, Meroni PI. Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants. Lupus. 2007;16(8):651-6.
• • Bianchi ML, Limonta C, Frasunkiewicz J, Biggioggero M, Vai S. Comment on: Bisphosphonates and osteonecrosis of the jaw. Rheumatology (Oxford). 2008 Mar;47(3):383; author reply 383-4.
• • Cimaz R, Meregalli E, Biggioggero M, Airò P, Danieli E, Antonioli CM, Motta M, Chirico G, Columbrita D, Frassi M, Meroni PL, Tincani A. Response to tetanus vaccination in infants exposed in utero to immunosuppressants for maternal autoimmune disorders. Lupus. 2007;16(2):129-32.
• • Cimaz R, Cazalis MA, Reynaud C, Gerloni V, Zulian F, Biggioggero M, Martini G, Pontikaki I, Fantini F, Mougin B, Miossec P. IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. Ann Rheum Dis. 2007 Jul;66(7):900-4.
• • Cimaz R, Borghi MO, Gerosa M, Biggioggero M, Raschi E, Meroni PL. Transforming growth factor beta1 in the pathogenesis of autoimmune congenital complete heart block: lesson from twins and triplets discordant for the disease. Arthritis Rheum. 2006 Jan;54(1):356-9.
• • Cimaz R, Biggioggero M, Catelli L, Muratori S, Cambiaghi S. Ultraviolet light exposure is not a requirement for the development of cutaneous neonatal lupus. Lupus. 2002;11(4):257-60.
• • Cimaz R, Biggioggero M. Osteoporosis. Curr Rheumatol Rep. 2001 Oct;3(5):365-70.

Lingue parlate

• • inglese
• • italiano

Enti e società scientifiche

• • Società Italiana di Reumatologia (SIR)

Abilitazione

• • Ordini Medici Chirurghi e Odontoiatri n. 39820 iscritto il 27/02/06

• • FASIE
• • PREVIMEDICAL
• • PRONTOCARE

Altre Informazioni

• Principali attività svolte:- Ambulatorio di diagnosi e gestione delle artriti precoci (Early Arthritis Clinic)- Partecipazione al progetto Miracle di collaborazione reumatologo-MMG- Ambulatorio terapie biologiche- Ambulatorio di Reumatologia- Ambulatorio di ecografia reumatologica- Ambulatorio di infiltrazioni articolari- Attività di ricerca- Partecipazione a congressi in qualità di relatore